Therapeutic Advances in Thrombosis

Managing patients with thrombotic vascular disease is complex and challenging: Ischemic vascular disease remains a complicated interplay of atherosclerosis and thrombosis—even with the evolution in our understanding of the pathobiology of thrombosis. There has been tremendous growth in therapeutic options which are quickly finding their place in daily practice, including a remarkable expansion in the number of intravenous and oral antithrombotic agents and new antiplatelet agents Now more than ever, all cardiologists, hematologists, and specialists in vascular medicine, as well as other professionals, such as hospital pharmacists, who deal with prognosis and intervention in preventing thrombosis, need a resource that distills current knowledge of this important subject. Written and edited by today’s leading international, Therapeutic Advances in Thrombosis, 2e provides physicians with the very latest in medical and surgical advances in antithrombotic therapies. With this comprehensively updated edition you get: Coverage of virtually all aspects of venous and arterial thrombotic disease and the corresponding therapies Strategies to manage specific clinical conditions and how to tailor treatment to individual patient needs Updated chapters covering thrombolysis in ST-elevated myocardial infarctions; thrombosis in patients with diabetes, pregnancy, and renal dysfunction Special emphasis on the pharmacology of novel anticoagulants and their practical use in venous thromboembolism and atrial fibrillation. Plus, all chapters fully explore clinical trial designs and outcomes for particular treatment therapies, as well as contain the relevant ACC/AHA/ESC guidelines, so you can confidently apply what you learn.

Table of Contents:
Contributors, vii Foreword, x Preface, xi 1 Arterial thrombosis: a brief overview, 1 Lina Badimon and Valentin Fuster 2 Aspirin, 12 Carlo Patrono 3 Platelet ADP P2Y12 inhibitors: thienopyridines, 26 Joseph D. Foley III and David J. Moliterno 4 Platelet ADP P2Y12 inhibitors: nonthienopyridines, 47 Joseph D. Foley III and David J. Moliterno 5 Cilostazol and dipyridamole: more than weak inhibition of platelets, 62 Wolfgang G. Eisert 6 Interrelationship of thrombin and platelets: the protease activated receptor-1, 71 Matthew E. Wiisanen and David J. Moliterno 7 Glycoprotein IIb/IIIa inhibitors, 87 Marco Valgimigli and Elisa Cangiano 8 Unfractionated heparin and low molecular weight heparin in ischemic heart disease, 111 Zafar Iqbal, Omar Hasan, and Marc Cohen 9 Pentasaccharide derivatives, 128 Antonio Gutierrez, Pierluigi Tricoci, and John H.P. Alexander 10 Intravenous direct thrombin inhibitors, 150 Femi Philip and A. Michael Lincoff 11 Vitamin K antagonists, 166 Freek W.A. Verheugt 12 Oral direct thrombin inhibitors and oral factor Xa inhibitors, 180 Steen Husted and Lars Wallentin 13 Thrombolytic therapy and concomitant antithrombotic therapies, 189 Peter R. Sinnaeve and Frans J. Van de Werf 14 Antithrombotic therapy in ST-segment elevation myocardial infarction, 205 Kurt Huber, Raffaele De Caterina, and Steen Dalby Kristensen 15 Antithrombotic therapy in non–ST-segment elevation acute coronary syndromes, 213 Georgios J. Vlachojannis, Vijayalakshmi Kunadian, Joseph M. Sweeny, and Roxana Mehran 16 Antithrombotic strategies in patients undergoing elective percutaneous coronary intervention, 236 Sunil V. Rao and E. Magnus Ohman 17 Antithrombotic management in patients with prosthetic valves, 246 Eric G. Butchart and Raffaele De Caterina 18 Stroke: thrombolysis and antithrombotic therapy, 272 L. Creed Pettigrew and Michael R. Dobbs 19 Atrial fibrillation: current and forthcoming antithrombotic therapies, 285 Raffaele De Caterina and Giulia Renda 20 Venous thromboembolism: pathophysiology, diagnosis, and prophylaxis, 306 Marco P. Donadini, Walter Ageno, and Alexander G. Turpie 21 Antithrombotic therapy in venous thrombosis and pulmonary embolism, 317 Marcello Di Nisio and Harry R. Büller 22 Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, hypercoagulable states, pregnancy, and renal insufficiency, 327 Meyer Michel Samama, Jacqueline Conard, and Grigoris Gerotziafas 23 Genetics of the response to antithrombotic drugs and the need for monitoring, 357 Jean-Philippe Collet, Gilles Montalescot, and Jean-Sébastien Hulot Index, 378

About the Author :
David Moliterno, M.D, co-director of the Gill Heart Institute, professor of Internal Medicine and division chief of Cardiovascular Medicine at the University of Lexington, Kentucky. He is also inaugurated as the American College of Cardiology Governor of the Kentucky chapter for the years 2007-2010. He has 189 articles published as listed on PubMed and is the author of the following books: Therapeutic Strategies in Thrombosis 1E; 900 Questions: An Interventional Cardiology Board Review. Raffaele De Caterina, MD, Institute of Cardiology, "G. d'Annunzio" University, Chieti, Italy. He has 261 articles published as listed on PubMed and is the author of the following books: Therapeutic Strategies in Thrombosis 1E; Endothelial Dysfunctions and Vascular Disease. Steen Dalby Kristensen, Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark. He has 91 articles published as listed on PubMed and is the author of the following books: Therapeutic Strategies in Thrombosis 1E.